tVNS and Prader-Willi Syndrome: What the Evidence Actually Shows

Why This Article?

Prader-Willi syndrome (PWS) is a rare, complex genetic neurodevelopmental disorder affecting approximately 1 in 15,000 to 25,000 births. It is caused by the absence of expression of paternally imprinted genes at chromosome 15q11.2-q13, arising through paternal deletion (65 to 75% of cases), maternal uniparental disomy (20 to 30%), or imprinting defects (1 to 3%).

The condition follows a distinctive developmental trajectory driven primarily by hypothalamic dysfunction. In infancy, severe hypotonia and feeding difficulties are the presenting features. In childhood and through adulthood, the hallmark hyperphagia develops: an insatiable appetite and obsessive food-seeking behaviour that, without environmental control, leads to life-threatening obesity. Behavioural features include temper outbursts, obsessive-compulsive behaviours, skin picking, anxiety, and difficulty with changes in routine. Endocrine dysfunction is pervasive, including growth hormone deficiency, hypogonadism, and hypothyroidism. Intellectual disability is typically mild to moderate.

Here is the point that frames everything else: there is no approved pharmacological treatment that addresses the core features of PWS. For hyperphagia, environmental management (locked kitchens, structured meal plans, constant supervision) remains the primary intervention. For the behavioural disturbances that are among the most distressing features of the condition, no targeted treatments exist. Temper outbursts are a leading cause of placement breakdown, restricted community access, and reduced quality of life for individuals and their families.

This is why there is genuine clinical interest in neuromodulatory approaches. The vagus nerve is centrally positioned in the pathways governing emotional regulation, autonomic function, appetite signalling, and inflammation, all of which are disrupted in PWS.

Anatomical Concepts distributes the tVNS® system in the UK. The tVNS® system is one of very few medical devices with regulatory approval specifically covering Prader-Willi syndrome. This article provides clinicians with a thorough overview of the evidence for tVNS in PWS, including an honest assessment of where the evidence is strong and where significant gaps remain.

The Clinical Challenge: Why PWS Is So Difficult to Treat

Hyperphagia

The hyperphagia of PWS is not simply "being hungry." It is a relentless, neurologically driven preoccupation with food that dominates the lives of individuals with PWS and everyone around them. Without constant environmental control of food access, it leads to morbid obesity and its complications. Individuals with PWS have markedly elevated circulating ghrelin levels from early childhood, preceding the onset of obesity, which is thought to contribute significantly to the hyperphagia. Several pharmacological approaches targeting appetite are under investigation, but none has received regulatory approval.

Temper Outbursts

Temper outbursts are among the most distressing features of PWS. They are characterised by explosive emotional reactions that can involve verbal aggression, physical aggression, and self-injury. The International PWS Clinical Trial Consortium has noted that effective therapies addressing these behavioural challenges have proven elusive. SSRIs have shown some benefit for compulsivity, and aripiprazole has been reported as helpful in approximately 70% of cases, but neither represents a targeted treatment.

Autonomic Dysfunction

PWS is associated with well-documented autonomic nervous system dysfunction characterised by diminished parasympathetic (vagal) activity. Studies using heart rate variability (HRV) analysis have shown reduced vagal tone during both wakefulness and sleep. Cardiovascular autonomic testing reveals impaired heart rate responses to active standing (47% of children) and deep breathing (22%). These abnormalities exist independently of obesity and may contribute to the increased cardiovascular risk observed even in young individuals with PWS.

Systemic Inflammation

PWS is associated with low-grade systemic inflammation that exists independently of obesity. Studies have documented elevated C-reactive protein, IL-6, IL-18, IL-1-beta, and TNF-alpha in individuals with PWS compared to both lean controls and adiposity-matched obese controls.

Why the Vagus Nerve? The Rationale

The rationale for vagal neuromodulation in PWS rests on several converging lines of evidence.

The Gut-Brain Axis and Appetite Regulation

The vagus nerve carries afferent signals from gut-based nutrient sensors to the nucleus tractus solitarius (NTS) in the brainstem. From the NTS, projections reach the hypothalamic arcuate nucleus and paraventricular nucleus, the brain's principal appetite-regulating centres. Satiety hormones (CCK, GLP-1) stimulate vagal afferent firing to signal fullness, while ghrelin suppresses vagal afferent discharge to signal hunger. By modulating vagal afferent activity, tVNS has the potential to shift the balance between orexigenic (hunger) and anorexigenic (satiety) signalling.

Research has shown that taVNS augments the postprandial decline in plasma ghrelin levels in healthy subjects (Kozorosky et al., 2022), providing a mechanistic link. However, the extent to which vagal pathways mediate ghrelin's actions in humans remains one of the unsolved questions in this field.

Autonomic Regulation

tVNS, by enhancing vagal tone, directly addresses the parasympathetic deficit documented in PWS. The 2024 case series by Schmausser and colleagues demonstrated that 12 months of tVNS produced measurable increases in circadian HRV amplitude and rhythm-adjusted HRV mean, with concurrent decreases in heart rate, all indicating increased cardiac vagal activity.

Behavioural and Emotional Regulation

The vagus nerve has extensive projections from the NTS to brain regions involved in emotional processing: the locus coeruleus (norepinephrine), the amygdala, the prefrontal cortex, and the nucleus accumbens. Vagal stimulation modulates the locus coeruleus-norepinephrine system, which regulates arousal, attention, and adaptive behaviour. It enhances prefrontal-amygdala connectivity, relevant to the emotional dysregulation seen in PWS.

Anti-Inflammatory Effects

The cholinergic anti-inflammatory pathway engaged by tVNS (vagal efferent activation leading to suppression of pro-inflammatory cytokines) provides a potential mechanism for modulating the inflammatory milieu that characterises PWS.

KEY POINT: The mechanisms by which tVNS may benefit PWS are multi-layered: modulation of appetite signalling via the gut-brain axis, correction of autonomic dysfunction, enhancement of emotional regulation through brainstem-limbic pathways, and anti-inflammatory effects. However, the clinical evidence to date points most strongly to improved behavioural regulation as the primary therapeutic benefit.

Why the Ear? The Anatomy Behind tVNS

The auricular branch of the vagus nerve (ABVN) provides the anatomical basis for transcutaneous stimulation. The cadaver dissection study by Peuker and Filler (2002) established that the cymba conchae has 100% vagal innervation, compared with approximately 45% at the tragus. The fMRI study by Frangos et al. (2015) confirmed in living humans that cymba conchae stimulation produces significant activation of the NTS, locus coeruleus, dorsal raphe, amygdala, and nucleus accumbens, with bilateral deactivation of the hypothalamus.

The hypothalamic deactivation finding is particularly relevant to PWS, where hypothalamic dysfunction is the central pathological feature underlying hyperphagia, endocrine deficiencies, and autonomic dysregulation.

This anatomical precision matters enormously: stimulation at the wrong site simply does not activate the brainstem pathways that drive the therapeutic effect.

The Clinical Evidence: What Do the Studies Show?

Let me be straightforward about the stage of evidence. The clinical literature on tVNS specifically for PWS consists of a small number of studies from a single research group at the University of Cambridge, led by Professor Anthony Holland and Dr Katie Manning. The total published sample size is approximately 8 individuals. This is the honest picture, and it reflects the challenges inherent in conducting clinical research in a rare condition.

Manning et al. (2016): Implanted VNS

The first study was an open-label case series of three adults with PWS who received surgically implanted vagus nerve stimulation for 12 months. The primary target was hyperphagia/overeating behaviour.

Changes in eating behaviour were equivocal. However, unanticipated, consistent beneficial effects were reported by two of three participants and their carers in maladaptive behaviour, temperament, and social functioning. The two responders asked to continue VNS after the study. At informal follow-up eight years later, both reported continuing benefits.

This was the serendipitous finding that shifted the focus from appetite to behaviour.

Manning et al. (2019): Transcutaneous VNS

This was the pivotal study. Five adults with PWS (all paternal deletion subtype, aged 22 to 41) received tVNS via the left cymba conchae for 12 months at 4 hours daily, followed by 1 month at 2 hours daily.

• Four of five participants demonstrated statistically significant reductions in outburst frequency and severity (p < 0.05)
• Improvements emerged after approximately 9 months of treatment
• Reducing to 2 hours daily led to increased outbursts in responders, demonstrating a dose-response relationship
• All four responders opted to continue treatment after the study
• One participant experienced mild skin irritation (resolved). No serious adverse events.

The dose-response finding is important: it strengthens the case for a genuine treatment effect rather than placebo response. The 9-month latency to response is consistent with the neuroplasticity-driven mechanisms of VNS observed in other conditions.

KEY POINT: The finding that 80% of participants (4 of 5) achieved significant reduction in temper outbursts is the basis for the tVNS® system's regulatory approval for PWS. However, this was a non-blind study with no sham control, and clinicians should understand this context when counselling patients and families.

Schmausser et al. (2024): Physiological Evidence

The same five participants were analysed using cardiac markers of circadian vagal activity. After 12 months of tVNS:

• Circadian amplitudes of HRV and heart rate were significantly higher at end of treatment compared to baseline (p < 0.01)
• Rhythm-adjusted mean of HRV significantly increased (p < 0.01) while heart rate mean significantly decreased
• Higher rhythm-adjusted mean HRV predicted lower number of emotional outbursts

This provided the first physiological evidence of a mechanistic link between tVNS-induced autonomic changes and behavioural improvement in PWS.

VNS4PWS Phase 3 Trial (Ongoing)

A Phase 3, randomised, double-blind, dose-ranging trial (NCT06144645) sponsored by the Foundation for Prader-Willi Research is currently recruiting. It compares two doses of tVNS over 9 months, followed by 3 months evaluating the effect of stopping treatment, plus a 1-year open-label extension. The primary outcome is reduction in temper outbursts, in individuals aged 10 to 40 with genetically confirmed PWS. This trial will provide the first blinded, controlled data for tVNS in PWS.

Indirect Evidence: tVNS and Appetite

Research in non-PWS populations provides mechanistic support:

• Kozorosky et al. (2022): taVNS significantly augmented the postprandial decline in plasma ghrelin levels in healthy subjects (p < 0.05)
• Obst et al. (2020): tVNS altered electrophysiological responses to food images, suggesting vagal stimulation modulates food cue processing
• Animal studies: taVNS reduces food intake and body weight gain in high-fat diet mice through a hypothalamic pathway

However, the implanted VNS study in PWS (Manning 2016) did not achieve its primary objective of reducing hyperphagia. tVNS for PWS should be discussed in terms of behavioural regulation, not appetite control, until evidence suggests otherwise.

Stimulation Parameters

Parameters Used in PWS Studies

Parameter	Value
Frequency	25 Hz
Pulse width	250 µs
Intensity	0.1 to 5.0 mA (set to detectable tingling)
Duration	4 hours daily
Duty cycle	30 seconds on / 30 seconds off
Site	Left cymba conchae
Treatment duration	12 months minimum

The finding that reducing from 4 hours to 2 hours daily led to worsening in responders suggests that a substantial daily stimulation duration may be necessary for behavioural benefits in PWS. The VNS4PWS Phase 3 trial is comparing two dose levels, which will provide the first dose-ranging data in this population.

Safety Considerations for PWS

The safety profile of tVNS in PWS from published studies is reassuring. No serious adverse events were reported. One participant experienced mild skin irritation at the electrode site, which resolved.

PWS-Specific Considerations

Skin picking: Present in 55 to 97% of individuals with PWS. The ear electrode site is not a typical location for skin picking, but clinicians should monitor the ear during treatment.

Compliance and routine: A 4-hour daily treatment requires careful integration into the daily routine. Once established, the structure may suit the preference for predictability that characterises PWS. A gradual introduction period is recommended.

Cognitive considerations: In most cases, a carer will need to manage the device. Instructions should be at an appropriate level.

Sensory sensitivity: Current intensity should be set carefully, starting low and increasing gradually.

Standard contraindications apply: Implanted cardiac devices, active implants, and broken skin at the electrode site.

Regulatory and Access Context

The tVNS® E device (tVNS Technologies GmbH, Germany) holds Class IIa certification under EU-MDR 2017/745, verified by TÜV SÜD. Prader-Willi syndrome is a specifically listed approved indication, alongside epilepsy, depression, and chronic migraine.

This regulatory approval is a meaningful distinction for a condition with few targeted treatments. It is one of very few medical devices with a specific PWS indication.

An important contextual note: CE marking under EU-MDR establishes that the device meets the regulatory standard for safety and clinical performance. The clinical evidence base for PWS consists of the small studies described above (total published tVNS sample of 5 individuals). Clinicians should understand the nature and extent of the underlying evidence when counselling patients and families.

There is currently no NICE guidance specific to tVNS for PWS. There is no FDA clearance for tVNS for PWS.

What We Don't Yet Know

Sample size: The total published tVNS sample in PWS is 5 individuals from a single study.

No blinded, controlled data yet: The Manning 2019 study was non-blind with no sham control. The VNS4PWS Phase 3 trial will address this gap.

Single research centre: All studies originate from the University of Cambridge. Independent replication is needed.

Genetic subtype: All participants had the paternal deletion subtype. Whether tVNS is equally effective in UPD or imprinting defect subtypes is unknown.

Age range: Published data covers adults aged 22 to 41. The Phase 3 trial includes ages 10 to 40.

Hyperphagia: The implanted VNS study did not show clear effects on eating behaviour. The appetite mechanism has not been demonstrated clinically in PWS.

Long-term outcomes: The longest follow-up is 13 months. Long-term efficacy and whether benefits persist after cessation are unknown.

Practical Guidance for Clinicians

Candidate Selection

• Individuals with genetically confirmed PWS experiencing frequent temper outbursts
• Age: published evidence in adults (22 to 41); Phase 3 trial includes 10 to 40
• A carer who can manage the device and treatment schedule
• Willingness to commit to a minimum 9 to 12 month trial at 4 hours daily
• Absence of cardiac pacemakers or implanted devices

Treatment Initiation

• Based on the Manning protocol: 25 Hz, 250 µs pulse width, 4 hours daily at the left cymba conchae
• Titrate intensity gradually to detectable tingling (0.1 to 5.0 mA)
• Introduce gradually over 1 to 2 weeks to establish routine
• Maintain a behavioural diary (outburst frequency and severity) from at least 4 weeks before starting

What to Tell Families

• In the published study, 4 of 5 adults with PWS experienced significant reductions in temper outbursts after approximately 9 months of daily tVNS use. This is an encouraging finding but comes from a small, unblinded study.
• The benefit takes time to develop. Allow at least 9 to 12 months of consistent use before judging response.
• The device is CE-marked specifically for PWS, which is a meaningful regulatory distinction.
• Side effects have been limited to mild, transient skin irritation.
• A larger, blinded clinical trial (VNS4PWS) is currently underway and will provide more definitive evidence.
• tVNS does not currently have strong evidence for reducing hyperphagia. Its demonstrated benefit is in reducing behavioural outbursts.

Monitoring

• Behavioural diary (outburst frequency, duration, severity)
• Regular skin inspection at electrode site
• Consider baseline and periodic HRV assessment
• Review at 3, 6, 9, and 12 months

Conclusion

The most honest summary is this: tVNS for Prader-Willi syndrome is a biologically rational, mechanistically coherent, and clinically promising intervention that is at an early stage of clinical evidence development.

The rationale is strong. The vagus nerve is centrally positioned in the pathways governing emotional regulation, autonomic function, appetite signalling, and inflammation, all of which are disrupted in PWS. The fMRI evidence confirms that auricular stimulation at the cymba conchae reaches the relevant brainstem and hypothalamic circuits.

The clinical evidence, while limited in volume, is internally consistent. Across all studies, the principal benefit is improved behavioural regulation, specifically reduced temper outbursts. The dose-response relationship and the physiological evidence of normalised autonomic function correlating with behavioural improvement add mechanistic coherence.

The tVNS® system's CE marking under EU-MDR specifically for PWS is a significant distinction for a condition with no approved pharmacological treatments for its core behavioural features. For individuals with PWS and their families, who live with daily challenges that have few effective interventions, this represents a legitimate clinical option.

The results of the VNS4PWS Phase 3 trial will be critically important. In the meantime, clinicians should present the evidence honestly, set realistic expectations about the timeline and likely benefits, and recognise that they are working at the frontier of an emerging evidence base in a condition that desperately needs effective treatments.

Related Literature

1. Manning KE, McAllister CJ, Ring HA, et al. Novel insights into maladaptive behaviours in Prader-Willi syndrome: serendipitous findings from an open trial of vagus nerve stimulation. J Intellect Disabil Res. 2016;60(2):149-155.

2. Manning KE, Beresford-Webb JA, Aman LCS, et al. Transcutaneous vagus nerve stimulation (t-VNS): a novel effective treatment for temper outbursts in adults with Prader-Willi syndrome indicated by results from a non-blind study. PLOS ONE. 2019;14(12):e0223750.

3. Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. 2002;15(1):35-37.

4. Frangos E, Ellrich J, Komisaruk BR. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul. 2015;8(3):624-636.

5. Holland AJ, Manning KE. t-VNS to treat disorders of behaviour in Prader-Willi syndrome and in people with other neurodevelopmental conditions. Auton Neurosci. 2022;239:102955.

6. Schmausser M, Holland A, Beresford-Webb J, et al. Effects of long-term transcutaneous auricular vagus nerve stimulation on circadian vagal activity in people with Prader-Willi Syndrome: a case-series. Res Dev Disabil. 2024;155:104834.

7. Qiu L, Chang A, Ma R, et al. Neuromodulation for the treatment of Prader-Willi syndrome: a systematic review. Neurotherapeutics. 2024;21(3):e00339.

8. Kozorosky EM, Lee CH, Lee JG, et al. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022;10(8):e15253.

9. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med. 2002;8(7):643-644.

10. Tauber M, Coupaye M, Diene G, Molinas C, Valette M, Beauloye V. Prader-Willi syndrome: a model for understanding the ghrelin system. J Neuroendocrinol. 2019;31(7):e12728.

11. Obst MA, Heldmann M, Alicart H, Tittgemeyer M, Munte TF. Effect of short-term transcutaneous vagus nerve stimulation (tVNS) on brain processing of food cues: an electrophysiological study. Front Hum Neurosci. 2020;14:206.

12. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14(1):10-26.

13. Tauber M, Hoybye C. Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction. Lancet Diabetes Endocrinol. 2021;9(4):235-246.

14. Dykens EM, et al. Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium. J Neurodevelop Disord. 2021;13:25.

15. Browning KN, Verheijden S, Boeckxstaens GE. The vagus nerve in appetite regulation, mood, and intestinal inflammation. Gastroenterology. 2017;152(4):730-744.

16. Redgrave J, Day D, Leung H, et al. Safety and tolerability of transcutaneous vagus nerve stimulation in humans: a systematic review. Brain Stimul. 2018;11(6):1225-1238.

Review current as of April 2026. Based on evidence available up to and including early 2026. The VNS4PWS Phase 3 trial (NCT06144645) is currently recruiting and its results will significantly update the evidence landscape.